LncRNA ABHD11-AS1 promotes the development of endometrial carcinoma by targeting cyclin D1.
Yao LiuLi-Li WangShuo ChenZhi-Hong ZongXue GuanYang ZhaoPublished in: Journal of cellular and molecular medicine (2018)
To investigate the expression, role and mechanism of action of long non-coding RNA (lncRNA) ABHD11-AS1 in endometrial carcinoma. The expression of lncRNA ABHD11-AS1 was quantified by qRT-PCR in human endometrial carcinoma (n = 89) and normal endometrial tissues (n = 27). LncRNA ABHD11-AS1 was stably overexpressed or knocked-down in endometrial carcinoma cell lines to examine the cellular phenotype and expression of related molecules. Compared to normal endometrial tissue, lncRNA ABHD11-AS1 was significantly overexpressed in endometrial carcinoma. Overexpression of lncRNA ABHD11-AS1 promoted the proliferation, G1-S progression, invasion and migration of endometrial cancer cells; inhibited apoptosis; up-regulated cyclin D1, CDK1, CDK2, CDK4, Bcl-xl and VEGFA; and down-regulated p16, while ABHD11-AS1 down-regulation has the opposite effect. RNA pull down demonstrated that lncRNA ABHD11-AS1 binds directly to cyclin D1. Knockdown of cyclin D1 can reverse the effect of ABHD11-AS1. Overexpression of lncRNA ABHD11-AS1 increased the tumorigenicity and up-regulated cyclin D1 in an in vivo model of endometrial cancer in nude mice. LncRNA ABHD11-AS1 functions as an oncogene to promote cell proliferation and invasion in endometrial carcinoma by positively targeting cyclin D1.
Keyphrases
- long non coding rna
- endometrial cancer
- poor prognosis
- cell cycle
- long noncoding rna
- cell cycle arrest
- transcription factor
- cell proliferation
- cell death
- endothelial cells
- gene expression
- binding protein
- type diabetes
- metabolic syndrome
- signaling pathway
- bone marrow
- endoplasmic reticulum stress
- mesenchymal stem cells
- skeletal muscle
- cancer therapy
- pi k akt